- Established in 2014
- Spin-out company from the Centre for Ophthalmology and Vision Sciences, Institute of Human Development, Faculty of Medical and Human Sciences
- Founded by Professor Paul Bishop
- Treatment of eye conditions including proliferative diabetic retinopathy and retinopathy of prematurity.
- IP – Patent
- Funded by UMIP Proof-of-Principle Funding, Medical Research Council’s Development Pathway Funding Scheme (University)
“The University does not just want to do great science, it also wants that science to make an impact.”
Professor Paul Bishop
Professor Paul Bishop, at the Centre for Ophthalmology and Vision Sciences in the Faculty of Medical and Human Sciences and Honorary Consultant Ophthalmologist at Manchester Royal Eye Hospital, CMFT, has discovered a human protein that prevents pathological blood vessel formation in the eye.
Paul and his colleagues discovered a protein, which they called opticin, that has potent anti-angiogenic properties and could be developed into a therapeutic drug for treating important causes of blindness: These include proliferative diabetic retinopathy (PDR), a complication of diabetes that affects approximately 17 million people worldwide, and a less common condition that affects premature babies called retinopathy of prematurity (RoP).
Both of these conditions are currently treated by applying multiple laser burns to the retina, which whilst often being effective, has major side effects including loss of peripheral (side) vision. It is anticipated that injecting Opticin into the eye will be an effective treatment for these conditions, but with fewer side-effects.
We met up with Paul to find out more about the company’s journey and his personal experiences of setting up a spin-out…